4,073,100 Shares in MiMedx Group, Inc $MDXG Bought by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY purchased a new position in shares of MiMedx Group, Inc (NASDAQ:MDXG - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,073,100 shares of the company's stock, valued at approximately $15,681,000. Paradigm Capital Management Inc. NY owned 2.79% of MiMedx Group as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of MDXG. DLD Asset Management LP acquired a new stake in shares of MiMedx Group during the second quarter worth about $289,000. Quantbot Technologies LP purchased a new stake in MiMedx Group in the second quarter valued at approximately $75,000. Ieq Capital LLC acquired a new position in MiMedx Group in the 2nd quarter worth approximately $650,000. E Fund Management Co. Ltd. acquired a new position in MiMedx Group in the 2nd quarter worth approximately $45,000. Finally, BlackRock Inc. purchased a new position in MiMedx Group during the 2nd quarter worth approximately $46,795,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MDXG has been the subject of several research reports. Citizens Jmp decreased their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a "market outperform" rating for the company in a research note on Thursday, April 30th. Weiss Ratings reiterated a "sell (d)" rating on shares of MiMedx Group in a research note on Thursday, August 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 target price on shares of MiMedx Group in a report on Monday, August 17th. Wall Street Zen downgraded shares of MiMedx Group from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st. Finally, Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, MiMedx Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.43.

MiMedx Group Stock Down 1.4%

Shares of MDXG stock opened at $4.27 on Tuesday. The stock has a 50 day moving average of $4.12 and a 200 day moving average of $4.11. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. The stock has a market cap of $622.40 million, a P/E ratio of 106.78 and a beta of 1.45. MiMedx Group, Inc has a twelve month low of $3.03 and a twelve month high of $7.97.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The business had revenue of $64.36 million for the quarter, compared to analysts' expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. As a group, sell-side analysts expect that MiMedx Group, Inc will post -0.1 EPS for the current year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source